Eosinophil-derived neurotoxin levels in early childhood and association with preschool asthma - A prospective observational study.
PreventADALL
asthma
child
eosinophil-derived neurotoxin
sex
type 2 inflammation
wheeze
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
01
09
2023
received:
21
02
2023
accepted:
19
09
2023
medline:
16
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Eosinophil-derived neurotoxin (EDN) is related to childhood asthma, while normal values are lacking. We aimed to document serum EDN levels at 1 and 3 years in general and in non-atopic children, and explore if EDN levels differed by sex or were associated with preschool asthma at 3 years. From the PreventADALL birth cohort, we included 1233 children with EDN analysed using ImmunoCAP at 1 and/or 3 years. Non-atopic children had no history of wheeze, asthma, allergic sensitization or atopic dermatitis. Preschool asthma was defined as having ≥3 episodes of bronchial obstruction between 2 and 3 years, plus doctor diagnosed asthma and/or asthma medication use by 3 years. The upper limit of normal (ULN) of EDN was defined as the 95th percentile. With Youden Index we calculated EDN cut-off levels for risk of preschool asthma. The overall median (ULN) EDN levels were 27.4 (121) μg/L at 1 year (n = 787), and 20.1 (87.8) μg/L at 3 years (n = 857). Non-atopic children had EDN levels of 24.0 (107) μg/L at 1 year (n = 147), and 17.3 (84.6) μg/L at 3 years (n = 173). EDN levels were higher in boys compared to girls; 32.0 (133) versus 24.5 (97.0) μg/L at 1 year, and 20.9 (96.3) versus 19.0 (72.4) μg/L at 3 years. Preschool asthma was observed in 109/892 (12.2%) children. Higher EDN levels at 1 (>26.7 μg/L) and 3 (≥20.5 μg/L) years were associated with preschool asthma; adjusted OR (95% CI) 2.20 (1.09, 4.41) and 4.68 (2.29, 9.55), respectively. We report EDN values in early childhood, demonstrating higher levels at 1 compared to 3 years and in boys compared to girls at both ages. Higher EDN levels at both ages were associated with preschool asthma. However, EDN cut-off levels for preschool asthma were overall lower than the ULN of non-atopic children, limiting translation into clinical practice.
Substances chimiques
Eosinophil-Derived Neurotoxin
EC 3.1.-
Biomarkers
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198-1211Subventions
Organisme : Arne Ingel's legat
Organisme : Barnestiftelsen at Oslo University Hospital
Organisme : Forte
Organisme : Fürst Medical Laboratory, Oslo, Norway
Organisme : Health and Rehabilitation Norway
Organisme : KI grants
Organisme : Norwegian Society of Dermatology and Venerology
Organisme : Oslo University Hospital
Organisme : Østfold Hospital Trust
Organisme : Region Stockholm
Organisme : Roche
Organisme : SFO-V Karolinska Institutet
Organisme : South-Eastern Norway Regional Health Authority
Organisme : Swedish Order of Freemasons Foundation Barnhuset
Organisme : The Cancer- and Allergy Foundation
Organisme : The European Union (MeDALL project)
Organisme : The Foundation for Healthcare and Allergy Research in Sweden -Vårdalstiftelsen
Organisme : The Frithjof Nansen Institute
Organisme : The Hesselman foundation
Organisme : The King Gustaf V 80th Birthday Foundation
Organisme : The Kloster foundation
Organisme : The Konsul Th C Bergh's Foundation
Organisme : The Magnus Bergwall foundation
Organisme : The Norwegian Association of Asthma and Allergy
Organisme : The Norwegian Research Council
Organisme : The Pediatric Research Foundation at Astrid Lindgren Children's Hospital
Organisme : The Samaritan Foundation for Pediatric research
Organisme : The Sven Jerring Foundation
Organisme : The Swedish Asthma- and Allergy Association's Research Foundation
Organisme : The Swedish Heart-Lung Foundation
Organisme : The Swedish Research Council - the Initiative for Clinical Therapy Research
Organisme : The Swedish Society of Medicine
Organisme : The University of Oslo
Organisme : Thermo Fisher Scientific, Uppsala, Sweden
Informations de copyright
© 2023 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Carraro S, Scheltema N, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur Respir J. 2014;44(6):1682-1696.
Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol. 2017;140(1):145-153.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed 9 October, 2020.
Lee YJ, Fujisawa T, Kim CK. Biomarkers for recurrent wheezing and asthma in preschool children. Allergy Asthma Immunol Res. 2019;11(1):16-28.
Kim CK. Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma. Korean J Pediatr. 2013;56(1):8-12.
Malinovschi A, Rydell N, Fujisawa T, Borres MP, Kim CK. Clinical potential of eosinophil-derived neurotoxin in asthma management. J Allergy Clin Immunol Pract. 2023;11(3):750-761.
Rutten B, Young S, Rhedin M, et al. Eosinophil-derived neurotoxin: a biologically and analytically attractive asthma biomarker. PLoS One. 2021;16(2):e0246627.
Granger V, Zerimech F, Arab J, et al. Blood eosinophil cationic protein and eosinophil-derived neurotoxin are associated with different asthma expression and evolution in adults. Thorax. 2022;77(6):552-562.
Rydell N, Nagao M, Ekoff H, Sjölander A, Borres M, Fujisawa T. Development of an automated ImmunoCAP research assay for eosinophil derived neurotoxin and its use in asthma diagnosis in children. Pract Lab Med. 2019;17:e00138.
Chakraborty S, Hammar KS, Filiou AE, et al. Longitudinal eosinophil-derived neurotoxin measurements and asthma development in preschool wheezers. Clin Exp Allergy. 2022;52(11):1338-1342.
An J, Lee JH, Sim JH, et al. Serum eosinophil-derived neurotoxin better reflect asthma control status than blood eosinophil counts. J Allergy Clin Immunol Pract. 2020;8(8):2681-2688.
Hoekstra MO, Hovenga H, Gerritsen J, Kauffman HF. Eosinophils and eosinophil-derived proteins in children with moderate asthma. Eur Respir J. 1996;9(11):2231-2235.
Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma. 2010;47(5):568-573.
Kim KW, Lee KE, Kim ES, Song TW, Sohn MH, Kim KE. Serum eosinophil-derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyperresponsiveness in childhood asthma. Lung. 2007;185(2):97-103.
Koller DY, Halmerbauer G, Frischer T, Roithner B. Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma? Clin Exp Allergy. 1999;29(6):786-793.
Remes S, Korppi M, Remes K, Savolainen K, Mononen I, Pekkanen J. Serum eosinophil cationic protein (ECP) and eosinophil protein X (EPX) in childhood asthma: the influence of atopy. Pediatr Pulmonol. 1998;25(3):167-174.
Kim CK, Kang DY, Callaway Z, et al. Increase in eosinophil-derived neurotoxin level in school children with allergic disease. Asia Pac Allergy. 2022;12(3):1-9.
Niggemann B, Kleinau I, Schmitt M, Wahn U. Twenty-four-hour time course of eosinophil granule proteins ECP and EPX during bronchial allergen challenges in serum of asthmatic children. Allergy. 1994;49(2):74-80.
Zimmerman B, Enander I, Zimmerman R, Ahlstedt S. Asthma in children less than 5 years of age: eosinophils and serum levels of the eosinophil proteins ECP and EPX in relation to atopy and symptoms. Clin Exp Allergy. 1994;24(2):149-155.
Rao R, Frederick JM, Enander I, Gregson RK, Warner JA, Warner JO. Airway function correlates with circulating eosinophil, but not mast cell, markers of inflammation in childhood asthma. Clin Exp Allergy. 1996;26(7):789-793.
Kim H, Kwon GE, Kim YH, et al. Comparison of serum eosinophil-derived neurotoxin levels between wheezing and non-wheezing groups in children with respiratory tract infection. J Asthma. 2020;57(11):1211-1215.
Kim CK, Choi J, Kim HB, et al. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr. 2010;156(5):749-754.
Skjerven HO, Lie A, Vettukattil R, et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2022;399(10344):2398-2411.
Lødrup Carlsen KC, Rehbinder EM, Skjerven HO, et al. Preventing atopic dermatitis and ALLergies in children-the PreventADALL study. Allergy. 2018;73(10):2063-2070.
Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-765.
Lødrup Carlsen KC, Roll S, Carlsen KH, et al. Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data from 11 European birth cohorts. PloS One. 2012;7(8):e43214.
Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2018;27(8):2374-2383.
Lødrup Carlsen KC, Halvorsen R, Carlsen KH. Serum inflammatory markers and effects of age and tobacco smoke exposure in young non-asthmatic children. Acta Paediatr. 1998;87(5):559-564.
Fitch PS, Brown V, Schock BC, Taylor R, Ennis M, Shields MD. Serum eosinophil cationic protein (ECP): reference values in healthy nonatopic children. Allergy. 1999;54(11):1199-1203.
Silva AC, Levy L, Trindade JC, Mendonça P, Silva C, Lopes AI. Faecal and serum levels of eosinophil cationic protein in a healthy paediatric population. Scand J Clin Lab Invest. 2007;67(7):757-766.
Li J, Zhang H, Huang X, Zhang J, Wu X. Establishment of reference intervals for complete blood count parameters in venous blood for children in the Xiamen area, China. Int J Lab Hematol. 2019;41(5):691-696.
Aldrimer M, Ridefelt P, Rödöö P, Niklasson F, Gustafsson J, Hellberg D. Population-based pediatric reference intervals for hematology, iron and transferrin. Scand J Clin Lab Invest. 2013 Apr;73(3):253-261.
Amaral R, Jacinto T, Malinovschi A, et al. The influence of individual characteristics and non-respiratory diseases on blood eosinophil count. Clin Transl Allergy. 2021;11(4):e12036.
Taniuchi S, Chihara J, Kojima T, Yamamoto A, Sasai M, Kobayashi Y. Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci. 2001;26(1):79-82.
Lee KY, Cho KJ, Kim YT, Kim JT. Serum eosinophil-derived neurotoxin in childhood atopic dermatitis: a useful marker of disease activity? Ann Allergy Asthma Immunol. 2009;102(6):532-534.
Bao Y, Chen Z, Liu E, Xiang L, Zhao D, Hong J. Risk factors in preschool children for predicting asthma during the preschool age and the early school age: a systematic review and meta-analysis. Curr Allergy Asthma Rep. 2017;17(12):85.
Rutten B, Young S, Aldridge S, et al. The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN). J Immunol Methods. 2022;500(1):1-5.
Sipahi S, Nacaroğlu HT, Can D, et al. Effect of socioeconomic status on allergic diseases and atopy in school children. Turk J Pediatr. 2017;59(6):670-677.
Knipping K, Knippels LM, Dupont C, Garssen J. Serum biomarkers for allergy in children. Pediatr Allergy Immunol. 2017;28(2):114-123.
Licari A, Castagnoli R, Brambilla I, et al. Asthma Endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol. 2018;31(2):44-55.
Rodriguez Del Rio P, Liu AH, Borres MP, Södergren E, Iachetti F, Casale TB. Asthma and allergy: unravelling a tangled relationship with a focus on new biomarkers and treatment. Int J Mol Sci. 2022;23(7):3881.